References

Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States

10.1053/j.gastro.2023.07.003 · 2023 · External reference

Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019

10.1136/bmjopen-2022-065186 · 2023 · External reference

Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies

10.1093/ecco-jcc/jjae082 · 2024 · External reference

Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort

10.1038/ajg.2010.343 · 2011 · External reference

Assessment and reporting of extraintestinal manifestations and fatigue in phase 3 inflammatory bowel disease clinical trials

10.1093/ecco-jcc/jjaf009 · 2025 · External reference

Beyond the gut: a systematic review and meta-analysis of advanced therapies for inflammatory bowel disease-associated extraintestinal manifestations

10.1093/ecco-jcc/jjae002 · 2024 · External reference

Emerging treatment options for extraintestinal manifestations in IBD

10.1136/gutjnl-2020-322129 · 2021 · External reference

Rayyan—a web and mobile app for systematic reviews

10.1186/s13643-016-0384-4 · 2016 · External reference

Unresolved reference

2000 · External reference

RoB 2: a revised tool for assessing risk of bias in randomised trials

10.1136/bmj.l4898 · 2019 · External reference

Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American gastroenterological association evidence synthesis

10.1053/j.gastro.2024.07.046 · 2024 · External reference

Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn’s disease

10.1111/apt.18110 · 2024 · External reference

Vedolizumab as induction and maintenance therapy for Crohn’s disease

10.1056/nejmoa1215739 · 2013 · External reference

Vedolizumab as induction and maintenance therapy for Ulcerative Colitis

10.1056/nejmoa1215734 · 2013 · External reference

Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

10.1111/apt.14930 · 2018 · External reference

Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis

10.1016/s2468-1253(21)00312-5 · 2021 · External reference

Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

10.1016/s2468-1253(21)00377-0 · 2022 · External reference

Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis

10.1016/j.cgh.2024.07.033 · 2025 · External reference

Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial

10.1016/j.jaad.2007.09.010 · 2008 · External reference

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

10.1016/j.jaad.2006.05.027 · 2006 · External reference

Efficacy and safety of continuous Risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial

10.1001/jamadermatol.2020.0723 · 2020 · External reference

Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial

10.1053/j.gastro.2012.01.035 · 2012 · External reference

Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial

10.1053/j.gastro.2006.11.041 · 2007 · External reference

Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

10.1016/s0140-6736(22)00466-4 · 2022 · External reference

ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease

10.1093/ecco-jcc/jjad108 · 2024 · External reference

The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis

10.1111/jgh.16612 · 2024 · External reference

Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease

10.1016/j.cgh.2016.06.025 · 2017 · External reference

P0894 impact of Mirikizumab on extraintestinal manifestations of Crohn’s disease in the VIVID-1 study

10.1093/ecco-jcc/jjae190.1068 · 2025 · External reference

P0587 Effectiveness and safety of Risankizumab in Crohn’s disease patients from a large Italian cohort: preliminary results from the RESOLVE IgIBD study

10.1093/ecco-jcc/jjae190.0761 · 2025 · External reference

P0885 therapeutic concepts for Pyoderma Gangrenosum as an extraintestinal manifestation in chronic inflammatory bowel diseases

10.1093/ecco-jcc/jjae190.1059 · 2025 · External reference

Effectiveness and safety of Upadacitinib induction therapy for 223 patients with Crohn’s disease: a GETAID multicentre cohort study

10.1111/apt.70073 · 2025 · External reference

P663 efficacy of jak inhibitors in inflammatory bowel disease patients with extraintestinal manifestations–retrospective study

10.1093/ecco-jcc/jjad212.0793 · 2024 · External reference

P941 Observational study of tofacitinib in ulcerative colitis in Sweden (ODEN) – Interim analysis of clinical and biomarker data

10.1093/ecco-jcc/jjad212.1071 · 2024 · External reference

Incidence and course of joint inflammation associated with inflammatory bowel disease in patients undergoing treatment with Vedolizumab/Ustekinumab: the VEDUSTAR study

10.3390/jcm13041076 · 2024 · External reference

Induction and maintenance of mucosal healing in Crohn’s disease with Ustekinumab in clinical practice across all care levels in Germany (MUCUS)

10.1038/s41598-024-70241-9 · 2024 · External reference

Effectiveness and safety outcomes after long-term (54 weeks) vedolizumab therapy for Crohn’s disease: a prospective, real-world observational study including patient-reported outcomes (POLONEZ II)

10.1177/17562848241293938 · 2024 · External reference

Persistence, effectiveness, and safety of Upadacitinib in Crohn’s disease and Ulcerative Colitis in real life: results from a Spanish Nationwide Study (Ureal Study)

10.14309/ajg.0000000000003243 · 2024 · External reference

Endo-histologic normalization is achievable with Tofacitinib and is associated with improved clinical outcomes

10.1007/s10620-022-07716-0 · 2023 · External reference

Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent

10.1111/apt.17305 · 2023 · External reference

Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases

10.1007/s10067-023-06695-5 · 2023 · External reference

Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study

10.1016/j.dld.2022.09.009 · 2023 · External reference

Impact of Vedolizumab on extraintestinal manifestations in inflammatory bowel disease: results from a descriptive, retrospective, real-world study

10.1093/ibd/izad075 · 2023 · External reference

Joint disease activity in inflammatory bowel disease-associated peripheral spondyloarthritis stratifies therapeutic response

10.1016/j.gastha.2021.12.002 · 2022 · External reference

Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy

10.1177/17562848211072412 · 2022 · External reference

OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): results from the UPA phase 3 programme

10.1093/ecco-jcc/jjab232.032 · 2022 · External reference

Su460 effectiveness of Ustekinumab for management of extraintestinal manifestations of Crohn’s disease

10.1016/s0016-5085(21)02382-9 · 2021 · External reference

The impact of ustekinumab on extraintestinal manifestations of Crohn’s disease: a post hoc analysis of the UNITI studies

10.1002/ueg2.12094 · 2021 · External reference

Ustekinumab for Crohn’s disease: two-year results of the Initiative on Crohn and Colitis (ICC) registry, a nationwide prospective observational cohort study

10.1093/ecco-jcc/jjab081 · 2021 · External reference

Effect of Ustekinumab on extraintestinal diseases in refractory Crohn’s disease

10.1093/ecco-jcc/jjab028 · 2021 · External reference

Low rate of drug discontinuation, frequent need for dose adjustment, and no association with development of new Arthralgia in patients treated with vedolizumab: results from a tertiary referral IBD center

10.1007/s10620-019-05982-z · 2020 · External reference

Vedolizumab for inflammatory bowel disease: two-year results of the Initiative on Crohn and Colitis (ICC) registry, a nationwide prospective observational cohort study: ICC registry - Vedolizumab

10.1002/cpt.1712 · 2020 · External reference

P100 real-world comparison of Arthralgias with Infliximab vs. Vedolizumab in the treatment of bio-naive inflammatory bowel disease

10.1093/ibd/zaa010.006 · 2020 · External reference

Effectiveness of Ustekinumab on Crohn’s disease associated spondyloarthropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

10.1080/14712598.2020.1830057 · 2020 · External reference

Ustekinumab for Crohn’s disease: results of the ICC registry, a nationwide prospective observational cohort study

10.1093/ecco-jcc/jjz119 · 2020 · External reference

Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s disease: a Gemini 2 post hoc analysis

10.1016/s0016-5085(17)32137-6 · 2017 · External reference

P703 The real-world long-term effectiveness of vedolizumab in inflammatory bowel diseases: a single-centre observational study

10.1093/ecco-jcc/jjy222.827 · 2019 · External reference

DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study

10.1093/ecco-jcc/jjy222.084 · 2019 · External reference

835 Can Ustekinemab relieve the symptoms of IBD-associated arthropathy?

10.14309/01.ajg.0000592876.05700.5e · 2019 · External reference

Long-term clinical effectiveness of Ustekinumab in patients with Crohn’s disease who failed biologic therapies: a national cohort study

10.1093/ecco-jcc/jjz080 · 2019 · External reference

Mo1899-joint pain in patients with inflammatory bowel disease treated with Vedolizumab: an extra-intestinal manifestation or a side effect of a gut-specific therapy?

10.1016/s0016-5085(18)32863-4 · 2018 · External reference

DOP025 Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID

10.1093/ecco-jcc/jjx002.062 · 2017 · External reference

The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases

10.1016/j.dld.2018.02.013 · 2018 · External reference

Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease

10.1136/annrheumdis-2016-211011 · 2017 · External reference

Adalimumab efficacy in enteropathic spondyloarthritis: a 12-mo observational multidisciplinary study

10.3748/wjg.v23.i39.7139 · 2017 · External reference

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from inspirada

10.1016/s0016-5085(17)32581-7 · 2017 · External reference

Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study

10.1097/mib.0000000000001109 · 2017 · External reference

Adalimumab treatment reduces extraintestinal manifestations in patients with moderate to severe Crohn’s disease: a pooled analysis

10.1016/s0016-5085(16)32634-8 · 2016 · External reference

Outcome of arthralgia in a subgroup of inflammatory bowel disease patients with anti tnf-alpha. A single centre study

10.1016/s1590-8658(13)60405-3 · 2013 · External reference

Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease

10.1007/s10620-013-2762-2 · 2013 · External reference

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn’s disease

10.4321/s1130-01082012000900004 · 2012 · External reference

Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

10.1136/gut.2005.074815 · 2006 · External reference

The effect of infliximab on extraintestinal manifestations of Crohn’s disease

10.1007/s00296-004-0467-8 · 2005 · External reference

Infliximab in the treatment of extra-intestinal manifestations of Crohn’s disease

10.1080/03009740510026698 · 2005 · External reference

Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations

10.1136/ard.2003.012450 · 2004 · External reference

Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease

10.1111/j.1572-0241.2003.07581.x · 2003 · External reference

Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn’s disease

10.1111/j.1572-0241.2002.06064.x · 2002 · External reference